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Protein quality control (PQC) plays an important role in
stemming neurodegenerative diseases and is essential
for the growth of some cancers. Valosin-containing pro-
tein (VCP)/p97 plays a pivotal role in multiple PQC path-
ways by interacting with numerous adaptors that link VCP
to specific PQC pathways and substrates and influence
the post-translational modification state of substrates.
However, our poor understanding of the specificity and
architecture of the adaptors, and the dynamic properties
of their interactions with VCP hinders our understanding
of fundamental features of PQC and how modulation of
VCP activity can best be exploited therapeutically. In this
study we use multiple mass spectrometry-based pro-
teomic approaches combined with biophysical studies to
characterize the interaction of adaptors with VCP. Our
results reveal that most VCP-adaptor interactions are
characterized by rapid dynamics that in some cases are
modulated by the VCP inhibitor NMS873. These findings
have significant implications for both the regulation of
VCP function and the impact of VCP inhibition on different
VCP-adaptor complexes. Molecular & Cellular Pro-
teomics 15: 10.1074/mcp.M116.061036, 2970–2986, 2016.
Protein Quality Control (PQC)1 is thought to play an impor-
tant role in human health, and mutations in key regulators of
PQC lead to neurodegenerative disease (1–4). PQC also is
a factor in cancer. During tumorigenesis, many genomic
changes occur, including aneuploidy, that place a high de-
mand on cellular mechanisms for coping with proteotoxic
stress, including PQC (5–7). The importance of PQC in cancer
is highlighted by the use of proteasome inhibitors to treat
multiple myeloma (MM) (8, 9). The success of proteasome
inhibitors as a therapy for MM has spurred interest in devel-
oping a deeper understanding of the significance of PQC to
the pathogenesis of cancer, and in identifying other critical
mediators of PQC that might serve as alternative targets for
therapy of cancer (8).
VCP (also known as p97), a homohexameric AAA ATPase,
participates in multiple PQC pathways, including ribosome-,
mitochondria-, and endoplasmic reticulum-associated degra-
dation (ERAD)(10–15) and mediates degradation of proteins
that misfold because of stress from heat or oxygen radicals
(16). VCP also has been implicated in processing of protein
aggregates and stress granules via autophagy (17–20). The
implication of VCP in PQC mediated by both the ubiquitin
proteasome system (UPS) and autophagy suggests that it
may serve as a critical node that orchestrates cellular PQC.
The function of VCP is modulated by “primary” binding
proteins, of which about two dozen well-validated partners
are known (21–23). Of particular interest is a set of adaptors
that are thought to serve as specificity factors that link sub-
strates to VCP. These adaptors often contain a VCP interac-
tion motif such as a UBX or PUB domain, and occasionally
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contain an ubiquitin-binding domain (24, 25). The N-terminal
region (N domain) of VCP can potentially bind 13 different
UBX domain adaptors as well as UFD1L-NPLOC4 (24). In
several cases, an adaptor plays an important role in linking
VCP to a specific substrate, e.g. (23, 26–29). However, as a
whole the adaptors remain poorly understood. Relatively few
adaptor-substrate pairs are known, and in addition little is
known about how exactly the adaptors work, including the
dynamics of their recruitment and dissociation, and whether
these processes are regulated by substrates or other factors.
Besides substrate adaptors, VCP also binds enzymes that are
thought to act upon VCP substrates. These include ubiquitin
chain-extending and chain-trimming enzymes that bind to
internal regions on VCP, as well as peptide-N-glycanase
which binds near the C terminus (30).
VCP depletion is toxic to cancer cells (31, 32) but is well-
tolerated by primary hepatocytes (33) and skeletal muscle in
vivo (34), suggesting that the VCP network may be a good
target for cancer therapy (8). To explore the potential of VCP
as a target for cancer therapy, we developed DBeQ and
ML240, which are reversible, competitive inhibitors of VCP
ATPase activity (31, 35). Subsequent optimization of ML240
yielded CB-5083 (36), which is currently being tested in phase
I clinical trials. CB-5083 is a potent inhibitor of the PQC
functions of VCP, and as a consequence triggers a massive
unfolded protein response that culminates in activation of
apoptosis (37). Recently, it was reported that the inhibitory
action of ML240 is blunted by the VCP adaptor NSFL1C/p47
(38). This suggests that VCP inhibitors may have selective
effects on different complexes, and motivates efforts to better
understand the assembly state of VCP in cells, and the impact
of VCP inhibitors on its assembly state.
New VCP functions and substrates have been sought
through the application of affinity purification-mass spectrom-
etry to identify proteins that bind to either VCP or its adaptors
(21, 23, 28, 39). These efforts have identified multiple new
functions for VCP, linking it to cullin-RING ubiquitin ligases,
endosomal sorting, and ciliary biogenesis. However, this ap-
proach is potentially hampered by the dynamics of adaptor-
VCP and substrate-adaptor interactions, which remain poorly
understood. Here, we take a multi-pronged strategy that com-
bines immunoprecipitation (IP)-mass spectrometry, cross-
linking, and size exclusion chromatography -mass spectrom-
etry to study VCP-interacting proteins. These studies revealed
that the interaction of VCP with its adaptors is exceptionally
dynamic and can be modulated by chemical inhibitors, which
we have verified and quantified by direct biophysical studies.
EXPERIMENTAL PROCEDURES
Mammalian Cell Culture—HEK293 cells (ATCC) and BJ fibroblasts
were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(Sigma-Aldrich, Natick, MA) supplemented with 10% heat inactivated
FBS, 100 g/ml streptomycin, and 100 IU/ml penicillin in 5% CO2 at
37 °C. Cells were washed with PBS, trypsinized, collected, and frozen
at 80 °C for further use.
SILAC Labeling of Cells—For SILAC experiments with HEK293T
cells, DMEM lacking arginine and lysine was supplemented with 10%
dialyzed fetal bovine serum (FBS), 1% L-glutamine, 1% Pen/Strep,
and 1 mM sodium pyruvate. Media used for cells grown in “heavy”
was supplemented with 50 mg/L of 13C6
15N2-lysine and
13C6-argi-
nine (Cambridge Isotope Laboratories, Tewksbury, MA) and 10 mg/L
of unlabeled proline, whereas media used for the growth of “light”
cells was supplemented with 50 mg/L of unlabeled lysine and arginine
and 10 mg/L of proline. Cells were grown in their respective media
until incorporation of heavy amino acids reached 98%, as deter-
mined by MS/MS analysis of derivatized amino acid hydrolysate.
CRISPR/Cas9-assisted Chromosomal Knock-in—A donor plasmid
(RDB3052) was designed to introduce the FLAG epitope tag se-
quences into the 5 end of the VCP coding sequence by homologous
recombination. The selection cassette and sequences from the 5 end
of the VCP gene comprising the FLAG sequence flanked by 300 bp
upstream and downstream of the VCP initiation codon were con-
nected by the 2A sequence (40). The modified PX330 plasmid (41)
(RDB3053) was used to cut the chromosomal VCP locus at the 5 end
of the open reading frame. The CRISPR protocol was then followed
(42) and mutant cells were selected for growth in the presence of
100g/ml Zeocin for 1 week. Surviving colonies were assayed by
PCR and Western blotting.
In-cell Cross-linking—In-cell cross-linking was performed using
Dithiobis[succinimidyl propionate] (DSP) (Thermo Fisher Scientific,
Waltham, MA). For each experiment, DSP was freshly prepared as a
200 mM stock solution in dimethyl sulfoxide (DMSO) and diluted to the
appropriate final concentrations in phosphate-buffered saline, pH 7.4
(PBS, Thermo Fisher Scientific). Cells were washed twice with PBS at
room temperature to remove residual medium and incubated with
DSP for 20 min at room temperature. After removal of the DSP, the
cross-linking reaction was quenched by incubating the cells with 25
mM Tris-HCl (pH 7.4) at room temperature for 10 min. The quenching
solution was then removed and the cells were frozen and stored at
80 °C.
Experimental Design and Statistical Rationale—SILAC experiment
for HEK293 cells treated with NMS873 or MG132 include total four
samples. Each SILAC comparison was done in biological duplicate,
and then the mass labels were swapped and the experiment repeated
in duplicate again. Label free experiment for BJ fibroblast and
HEK293 treated with NMS873 or MG132 includes 6 samples in total.
Each treatment including control was done separately with biological
duplicates. SEC-MS experiment for HEK293 cells treated with
NMS873 includes three biological replicates, which contains 16 MS
runs each. Two-tailed Student’s t test was applied to analyze chro-
matographic peak shift and intensity change. Statistical process for
individual experiment would be discussed in following sessions.
Size Exclusion Chromatography for Protein Lysate Fractionation—
Cells were collected and lysed by sonication in buffer B (25 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1:10000 diluted protease inhibitor
mixture (Roche, Basel, Switzerland)) on ice. The chilled lysates were
then centrifuged in a SS34 rotor at 13,200  g for 20 min at 4 °C. The
cleared supernatant was filtered through a 0.45 m syringe filter
before chromatographic separation. All the samples were normalized
based on protein concentration. Size exclusion chromatography was
performed on a 24 ml Superose 6 column using an AKTA FPLC
system and standard purification templates (GE Healthcare Biosci-
ences, Uppsala, Sweden). The column was equilibrated and then
developed in buffer B until the absorption of the flow-through re-
turned to baseline. Sixty fractions of 400 l each were collected and
every third fraction from #11 through #58 was processed for further
mass spectrometry analysis.
Protein Digestion of SEC Fractions—Frozen elution fractions from
the NMS-873 and VCP knockdown experiments were obtained, along
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with wild-type HEK293 fractions prepared alongside each perturba-
tion. Experiments were performed in biological triplicate. To mitigate
significant nontryptic peptide activity, urea was added to each frac-
tion prior to thawing for a final concentration of 8 M. Samples were
sonicated until urea was completely dissolved, then incubated with 10
mM tris(2-carboxyethyl)phosphine (TCEP) and 40 mM chloroacet-
amide (CAA) at room temperature for 10 min. Fractions were then
pooled by threes, to create 12 final fractions per replicate. Pooled
fractions were concentrated on centrifugal filters (Amicon Ultra 0.5 ml
Ultracel membrane10 kDa) to 100 l. Samples were diluted with 50
mM Tris pH 8 to 1.5 M urea, then digested overnight at room temper-
ature with 3 g trypsin (Promega, Madison, WI). Samples were acid-
ified with 0.1% trifluoroacetic acid (TFA), then desalted using SepPak
C18 solid-phase extraction (SPE) cartridges (Waters, Milford, MA).
SPE cartridges were equilibrated with one column volume of 100%
acetonitrile (ACN), followed by 0.1% TFA. Acidified samples were
loaded on column, followed by washing with three column volumes of
0.1% TFA. Peptides were eluted off the column by the addition of 0.7
ml of 40% ACN with formic acid 0.1% TFA and 0.5 ml 80% ACN with
0.1% TFA. Eluates were dried overnight in a SpeedVac concentrator
(Thermo Fisher Scientific), and resuspended in 75 l of 0.2% formic
acid.
Mass Spectrometry Analysis of SEC Fractions—Peptides were in-
jected on to a reverse-phase column prepared in-house. Approxi-
mately 35 cm of 75 m-360 m inner-outer diameter bare-fused silica
capillary, each with a laser pulled electrospray tip, were packed with
1.7 m diameter, 130 Å pore size, Bridged Ethylene Hybrid (BEH) C18
particles (Waters). Columns were fitted on to a nanoAcquity (Waters)
and heated to 55–65 °C using a home-built column heater. Mobile
phase buffer A was composed of water and 0.2% formic acid. Mobile
phase B was composed of 100% ACN, 0.2% formic acid, and 5%
DMSO. Each sample was separated over a 100-min gradient, includ-
ing time for column re-equilibration. Flow rates were set at 300–350
l/min.
Peptide cations were converted to gas-phase ions by electrospray
ionization and analyzed on a Thermo Orbitrap Fusion (Q-OT-qIT,
Thermo). Precursor scans were performed from 300 to 1500 m/z at
60K resolution (at 400 m/z) using a 5  105 AGC target. Precursors
selected for tandem MS were isolated at 1 Th with the quadrupole,
fragmented by HCD with a normalized collision energy of 30, and
analyzed using rapid scan in the ion trap. For some analyses, precur-
sors above 500 m/z and signal to noise ratio higher than 1.5 were
fragmented by HCD using the described conditions, whereas precur-
sors below 500 m/z were fragmented by CAD with a normalized
collision energy of 30. The maximum injection time for MS2 analysis
was 35 ms, with an AGC target of 104. Precursors with a charge state
of 2–6 were sampled for MS2. Dynamic exclusion time was set at
15 s, with a 10 ppm tolerance around the selected precursor and its
isotopes. Monoisotopic precursor selection was turned on. Analyses
were performed in top speed mode with 5 s cycles.
The raw files were searched directly against the Homo sapiens
database with nonredundant entries (20,198 entries) using Androm-
eda on Maxquant (Version 1.5.2.8). The proteome database also
includes four SEC elution standards (bovine thyroglobulin, bovine 
globulin, chicken ovalbumin, and horse myoglobin). Searches were
performed using a precursor search tolerance of 4.5 ppm and a
product mass tolerance of 0.35 Da. Search criteria included a static
modification of 57.0214 Da on cysteine residues, dynamic modifi-
cation of 15.9949 Da on oxidized methionine and N-terminal acety-
lation of  42.0106 Da. Searches were performed with full tryptic
digestion and allowed a maximum of two missed cleavages on pep-
tides analyzed by the sequence database. False discovery rates (FDR)
were set to 1% for each analysis.
SEC Chromatogram Analysis—To determine how each treatment
(VCP knockdown and incubation with NMS-873) affected how pro-
teins eluted off the SEC column, we calculated an apex shift metric.
We are defining “apex” as the fraction in which the majority of the
protein elutes. Apex shift was calculated by generating an average
fraction number weight against the percent of the total protein that
eluted in each fraction. Fractions were numbered 1 through 12, with
fraction 1 containing the largest MW proteins/complexes, and fraction
12 containing the smallest. Percent protein per fraction was calcu-
lated by first summing the LFQ intensities across the fractions for
each protein, then dividing the LFQ intensity in each fraction by the
total LFQ intensity in all fractions. The average apex for each protein
was then calculated by multiplying each fraction number by the
percent protein per fraction, then summing the results. The sum then
represents the fraction number in which the majority of the protein
elutes, taking into account the spread of the protein across all frac-
tions as well. To calculate average apex shift, we first averaged the
apices across biological replicates, then subtracted the mean apex
fraction of the wild-type from the mean apex fraction of the corre-
sponding treatment: in doing so, a positive apex shift indicated elution
of a protein at a lower molecular weight after treatment than in the
wild-type, and a negative shift indicated elution at a higher molecular
weight after treatment. p values were calculated from the apex frac-
tion numbers across replicates using a two-tailed Student’s t test.
Fold-change calculations were made on total protein across all frac-
tions; LFQ intensities were summed across fractions, log2 trans-
formed, and averaged, then the mean log2 intensities from the wild-
type samples were subtracted from the mean log2 intensities in their
corresponding treatment samples. p values were calculated from the
log2 LFQ intensities across replicates using a two-tailed Student’s t
test.
Western Blotting to Evaluate Fractionation of VCP Adaptors Upon
Size Exclusion Chromatography—Samples from cell lysate were pre-
pared by size exclusion chromatography as before, with the addi-
tion of 0.05% Triton X-100 in the lysis buffer. Samples were run on
a 4–20% gradient SDS-PAGE Gel (Thermo Fisher Scientific), trans-
ferred to a nitrocellulose membrane, blocked with 5% milk in
TBS-T, incubated with the appropriate primary and secondary an-
tibodies, and developed using Immobilon Western Chemilumines-
cent HRP Substrate (Millipore) with film. Antibodies used are anti-
VCP rabbit polyclonal (Santa Cruz), anti-UBXN7 rabbit polyclonal
(EMD Millipore, Billerica, MA), anti-UBXN6 mouse monoclonal (gift
from Dale Haines), and anti-UFD1L mouse monoclonal (BD Biosci-
ences), goat anti-rabbit HRP conjugate (Santa Cruz, Biotechnology,
Dallas, Texas), and goat anti-mouse HRP conjugate (Santa Cruz,
Biotechnology).
Immunoprecipitation/Western Blotting/Mass Spectrometry—Cells
were collected and lysed by sonication in buffer A (25 mM Tris-HCl pH
7.4, 150 mM NaCl, 1 mM EDTA, 5% glycerol, 1% Nonidet P-40, and
1 protease inhibitor mixture (Roche)) on ice. Lysates were cleared of
debris by centrifugation at 16,000  g for 5 mins and normalized
based on protein concentration. One mg of lysate was incubated with
0.2 l antibodies (Anti-VCP, Abcam ab11433 or Anti-FLAG, Sigma
F1804) at 4 °C with rotation for the specified times. The reactions
were then supplemented with 20 l of Protein A/G magnetic beads
(Thermo Scientific, 88802) and incubated for 5 min at room temper-
ature. The beads were washed twice with 400 l of buffer A followed
by two washes with 25 mM Tris-HCl pH 7.4. Immunoprecipitates were
subsequently processed for Western blotting or mass spectrometry
as described below.
To detect immunoprecipitated proteins by Western blotting, bound
proteins were eluted by boiling the Protein A/G beads in SDS loading
buffer supplemented with 50 mM DTT for 5 min. The eluents were
separated on a 10% SDS-polyacrylamide gel and transferred onto a
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nitrocellulose membrane. The membranes were probed using anti-
bodies against proteins of interest.
To detect immunoprecipitated proteins by mass spectrometry, a
buffer containing 5 mM dithiothreitol, 8 M urea, and 50 mM Tris-HCl,
pH 8 was added to the beads. Reduced cysteines were then alkylated
by treating the sample with 15 mM iodoacetamide for 30 min. at room
temperature, in the dark. After reduction and alkylation, the sample
was digested with LysC at a volume ratio of 1:100 (enzyme/sample)
for 2 h at room temperature. After LysC digestion, the urea was
diluted to 2 M and trypsin was added at a volume ratio of 1:50
(enzyme/sample) and allowed to digest overnight at 25 °C. The next
day, tryptic peptides were desalted using a Sep-pak C18 column
(Waters) and lyophilized to dryness.
Mass Spectrometric Data Acquisition—Peptide samples were dis-
solved in 80 l of 0.2% formic acid and injected into an EASY II
nano-UPLC (Thermo Scientific) system. Reverse phase chromatog-
raphy was performed using a 15 cm silica analytical column with a 75
m inner diameter packed in-house with reversed phase ReproSil-
Pur C18AQ 3 m resin (Dr Maisch GmbH, Amerbuch-Entringen, Ger-
many). The mobile phase buffer consisted of 0.2% formic acid in
mass spectrometry grade water with an eluting buffer of 0.2% formic
acid in 80% CH3CN (Buffer B) run over a linear gradient (8–35%
Buffer B, 120 min) and using a flow rate of 350 nL/min. The HPLC
system was coupled online with a high-resolution Orbitrap mass
spectrometer (LTQ-Orbitrap Elite; Thermo Scientific). The mass spec-
trometer was operated in the data-dependent mode in which a full-
scan MS (fromm/z 300–1700 with the resolution of 60,000 atm/z 400)
was followed by 20 MS/MS scans of the most abundant ions using
collision-induced dissociation (CID). Ions with a charge state of 1
were excluded and the dynamic exclusion time was set to 60 s after
two fragmentations.
Database Search and Quantification—The raw files were searched
directly against the Homo sapiens database with nonredundant en-
tries (20,198 entries; human Swiss-Prot downloaded on Jan, 2014)
using Andromeda on Maxquant (Version 1.5.2.8). Peptide precursor
mass tolerance was set to 10 ppm, and MS/MS tolerance was set to
0.8 Da. Search criteria included a static modification of 57.0214 Da
on cysteine residues, a dynamic modification of 15.9949 Da on
oxidized methionine. Searches were performed with full tryptic diges-
tion and allowed a maximum of two missed cleavages on peptides
analyzed by the sequence database. False discovery rates (FDR) were
set to 1% for each analysis. For protein-protein interaction analysis,
published genetic and physical interactions with VCP were obtained
from the BioGRID (43) database, version 3.4.135.
Recombinant Protein Expression and Purification—Full-length VCP
was amplified by PCR from human VCP pET15_T(38) and ligated into
pET24b using NdeI/SalI to produce a noncleavable C-terminal His-
tagged construct (RDB3219). For FRET studies, VCP coding se-
quences were amplified by PCR and ligated into a modified pET28a
vector to produce a construct with a noncleavable C-terminal His-tag
and an N-terminal ybbR tag with a short linker (MDSLEFI-
ASKLAGGGS). Human ND1L (1–480) pET24b construct (RDB2945) is
previously described (38). The construct for full-length NSFL1C with
a noncleavable N-terminal His-tag (44) was obtained through Add-
gene (#21268), and site-directed mutagenesis was used to make a
NSFL1C-Thr370Cys mutation. Proteins were expressed and puri-
fied as described previously (38), with the exception that NSFL1C
was expressed in TOP10 cells for 3 h at 37 °C. For FRET, NSFL1C-
Thr370Cys was incubated with tetramethylrhodamine-5-maleimide
(ThermoFisher) prior to gel filtration to produce NSFL1CTAMRA. For
ybbR labeling, Cy5-CoA conjugate and Sfp enzyme were made as
described (45). Thirty micromolar ybbR-VCP was incubated for at
least 3 h at room temperature with 60 M Cy5-CoA conjugate and
12 M Sfp in 50 mM HEPES pH 7.4, 10 mM MgCl2 prior to gel
filtration. All proteins were purified on a Superose 6 gel filtration
column.
FRET Measurements—All FRET measurements were carried out in
20 mM HEPES, pH 7.4, 100 mM KCl, 3 mM MgCl2, 1 mM TCEP, and 1
mg/ml ovalbumin (Sigma). Nucleotides were optionally present at 2
mM, and inhibitors were optionally present at 15 M. Equilibrium
binding assays were carried out on a FluoroLog-3 (Jobin Yvon), with
excitation at 540 nm and emission scan 555–750 nm. Stopped-flow
experiments were carried out on a Kintek SF-300X instrument with
excitation at 540 nm and a 580/20 emission filter. Data were analyzed
using Prism 6 (GraphPad).
RESULTS
Study of VCP Complex Assembly Using Size Exclusion
Chromatography-mass Spectrometry—To investigate VCP’s
association with its adaptors and other binding partners, we
sought to employ size exclusion chromatography (SEC) in a
buffer containing no detergent and low salt, with the idea that
gentle conditions might preserve the integrity of native protein
complexes. For these experiments, we prepared lysates from
HEK293 cells that were untreated, supplemented with
NMS873 for 6 h, or depleted of VCP by doxycycline induction
of shRNA (supplemental Fig. S1A). The lysates were fraction-
ated on a gel filtration column, and every third fraction was
analyzed by shotgun mass spectrometry.
To evaluate the fractionation behavior of the 7919 proteins
identified in three biological replicates of both the control
versus NMS873-treated or control versus VCP knock-down
experiments, we developed an algorithm that estimated the
relative amount of each protein by label-free quantification, as
well as the mean fractionation position (apex) on the size
exclusion column. A histogram summarizing the apex shifts
for all proteins identified in the perturbation experiments as
well as an untreated versus untreated control is shown in Fig.
1A. The variability in the fractionation behavior of known VCP
adaptors, number of identified proteins in each experiment,
and changes in protein level observed upon depletion or
inhibition of VCP are plotted in supplemental Figs. S1B–S1D.
The fractionation behavior of all 8000 proteins is consoli-
dated in supplemental Table S1 and fully listed in supplemen-
tal Table S2.
We observed that for both NMS873 treatment and VCP
knockdown, there was a bias for proteins increasing in mo-
lecular weight (i.e. eluting in any earlier fraction, possibly
because of accumulation in larger protein complexes) and
decreasing in abundance, with the bias being stronger for the
former (Fig. 1B, 1C). The known functions of VCP in protein
complex disassembly (12, 13) suggested we might observe a
bias for proteins increasing in molecular weight and abun-
dance following VCP inhibition, as these proteins would re-
main trapped in complexes (including complexes with VCP in
the case of NMS873 treatment) and unavailable to the pro-
teasome for degradation. Some of these proteins may asso-
ciate with membranes, chromatin, or other sedimentable
structures, which, given that our lysis buffer did not include
detergent or nucleases, could explain their unexpected ap-
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parent decrease in abundance. Proteins that shifted in molec-
ular weight in response to VCP inhibition do not share biological
functions (supplemental Fig. S1E). Few of the proteins we iden-
tified as changing in molecular weight and abundance following
VCP modulation had been previously reported as VCP-associ-
ated (supplemental Fig. S1F, S1G). The proteome elution pat-
tern in our SEC experiments generally agrees with a previous
data set generated by Kirkwood and coworkers (46).
Using the data set in supplemental Table S1, we generated
theoretical chromatograms for VCP and a subset of its adap-
tors. For this investigation we focused on UFD1L-NPLOC4
and the putative substrate-recruiting UBX domain adaptors
that bind the N-terminal domain, of which 12 were identified
(theoretical chromatograms for these proteins are shown in
Figs. 2A–2D and supplemental Figs. S2A–S2C and the repro-
ducibility of their fractionation across triplicates is shown in
FIG. 1. Analysis of the fractionation
behavior of cellular proteins by SEC-
mass spectrometry in response to
modulation of VCP activity. HEK293
cell lysate from untreated or perturbed
cells was chromatographed on a Super-
ose-6 column, and every third fraction
was subjected to shotgun sequencing
by mass spectrometry. A, Histogram of
apex shifts of proteins in treated cells
relative to control cells (Atreated Acontrol)
for all 7919 proteins identified in the
SEC-MS analysis. The apex for each
protein is defined as the fraction in which
the protein is present in the highest
amount. Plotted data are the average of
triplicates. B, Molecular weight shift and
abundance fold change (log scale) in re-
sponse to VCP knockdown compared
with control knockdown. Proteins in area
that is not grayed out represent those
with 2.5 mean apex shift. Of these
proteins, enrichment for a  fourfold
change in abundance (those above or
below the horizontal dotted lines), rela-
tive to all proteins identified by SEC-MS,
was calculated. The average values of
triplicate measurements are reported. C,
Same as panel B, except that cells were
mock-treated or treated with 10 M
NMS873 for 6h.
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supplemental Fig. S2D). Evaluation of their fractionation be-
havior in untreated versus perturbed cells revealed that they
could be segregated into four distinct classes as follows.
Class I adaptors, comprising UBXN2A and ASPSCR1, ex-
hibited strong cofractionation with VCP in untreated cells, and
were not affected by NMS873 treatment (supplemental Fig.
S2A). Class I adaptors appear to have a more stable associ-
ation with VCP than other adaptors. Moreover, UBXN2A levels
were reduced below detection upon VCP depletion (supple-
mental Fig. S2A), suggesting that its stability was dependent
upon assembly with VCP. ASPSCR1 was not affected by VCP
depletion, but it should be noted that only 80% depletion of
VCP was achieved and thus VCP may still have been present
in sufficient amounts to saturate ASPSCR1.
UBXN4, UBXN8, and FAF2 define Class II VCP adaptors,
which were constitutively assembled in complexes of higher
MW than the VCP peak regardless of whether or not VCP was
depleted or inhibited with NMS873 (supplemental Fig. S2B;
note that UBXN8 was not detected in the experiment with
VCP-depleted cells). Thus, the high MW forms of these pro-
teins presumably arose from assembly with proteins other
than VCP. Interestingly, UBXN4 and UBXN8 are ER mem-
brane proteins, yet our analysis was performed on cell lysates
prepared without detergent. It is not known whether the forms
of UBXN4/8 detected here are in small vesicles or are proteo-
lytic fragments released from the ER.
The Class III adaptors UBXN2B, NSFL1C, and UBXN1,
migrated at MWs lower than the VCP peak, and were not
affected by either chemical inhibition or depletion of VCP
(supplemental Fig. S2C).
The Class IV adaptors UFD1L, NPLOC4, UBXN7, and FAF1
migrated primarily at MWs lower than the VCP peak in unper-
turbed cells (Fig. 2A), but a substantial fraction of each was
recruited into high MW complexes upon inhibition of VCP with
NMS873 (Fig. 2B). Formation of these higher MW complexes
was not an indirect consequence of a reduction of VCP ac-
tivity, because a similar shift in MW was not observed in cells
depleted of VCP (Fig. 2C, 2D). This suggests that NMS873
stabilized formation of high MW complexes between these
adaptors and VCP.
The only adaptor that did not fit neatly into Classes I-IV is
UBXN6. In the presence of NMS873, UBXN6 shifted to higher
MW like UBXN7, but in the depletion experiment it partitioned
into high and low MW complexes (Fig. 2A–2D). We note that
the theoretical chromatograms for VCP, UBXN6, UBXN7, and
UFD1L match the fractionation of these proteins as deter-
mined by Western blotting of SEC fractions (supplemental Fig.
S2E). We also note that retrospective analysis of theoretical
chromatograms derived from a data set generated by Kirk-
wood et al. (46) (supplemental Fig. S2F) yielded results for
unperturbed cells similar to ours with the exception of UBXN6,
which exhibited a high MW peak in our data set but not theirs,
and UBXN4 and UBXN8, which were not detected in their
data set, most likely because they did not analyze very high
MW fractions (e.g. as shown in supplemental Fig. S2F Kirk-
wood et al. did not capture the entire VCP peak, whereas we
did, as shown in supplemental Figs. S2A–S2C).
VCP-adaptor Interactions Are Exceptionally Dynamic—The
results of the SEC-mass spectrometry took us by surprise,
because even well-studied adaptors like UFD1L-NPLOC4,
UBXN7, and NSFL1C showed little or no cofractionation with
VCP in unperturbed cells. This suggested to us that VCP
might exhibit much more dynamic association with its adap-
tors than was previously appreciated. To address this ques-
FIG. 2. Analysis of the fractionation be-
havior of VCP and its adaptors by SEC-
mass spectrometry in response to modu-
lation of VCP activity. A, The relative LFQ
intensity of peptides from VCP and Class IV
adaptors in SEC fractions from untreated
HEK293 cells were averaged to generate an
estimate of the level of these proteins in each
fraction. These levels were then plotted.
Quantitative data on the behavior of tripli-
cates for each protein are provided in supple-
mental Fig. S2D. B, same as panel A, except
that cells were treated with 10 M NMS873 for
6 h prior to lysis. C, Same as panel A, except
that cells were transfected with control
shRNA 96 h prior to lysis. D, Same as panel A,
except that cells were transfected with
shRNA against VCP sequences 96 h prior to
lysis.
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tion, we performed conventional affinity purification-mass
spectrometry experiments. The first approach we took was
to immunoprecipitate VCP from HEK293 cell lines in which
the genomic locus of VCP was modified using CRISPR/
Cas9 technology (47) to encode VCP with a FLAG epitope
appended to its N terminus (HEK293FLAGVCP cells). Al-
though we successfully obtained cell lines that expressed
endogenous VCP bearing an N-terminal FLAG tag (FLAGVCP,
supplemental Fig. S3A), we were unable to obtain cell lines in
which all alleles of VCP were tagged, suggesting that this
might be a lethal event.
Shotgun mass spectrometry following immunoprecipitation
(IP) of endogenous FLAGVCP retrieved with anti-FLAG resin
consistently yielded hundreds of proteins. To determine how
many of these proteins were likely to be specific VCP bind-
ing partners as opposed to nonspecific contaminants, we
performed a control experiment in which lysate from
HEK293FLAGVCP cells grown in medium containing heavy ly-
sine and arginine was mixed with lysate from untagged
HEK293 cells grown with light lysine and arginine (referred to
here as a purification after mixing (PAM)-SILAC protocol) (48).
Anti-FLAG IP for 60 min followed by mass spectrometry re-
vealed that a large fraction of the identified proteins had log2
H/L ratios between 1 and 1 (supplemental Table S3), which
is a range that many false positives fall in because of analyt-
ical error (49). However, given the poor cofractionation of
adaptors observed in the SEC-mass spectrometry experi-
ments as well as results from unrelated studies in which we
observed a remarkable level of exchange of F-box proteins
during IP of Cul1 (J.M.R., unpublished data), we wondered
whether the small number of proteins with H/L log2 ratios 1
might be because of exceptionally dynamic association of
VCP with its physiological partners. To assess this possibility,
we repeated the analysis, but in this case we performed a
mixing after purification (MAP)-SILAC experiment (48) in
which tagged heavy and untagged light samples were sub-
jected to IP separately and then mixed immediately before
LC-MS/MS analysis (Fig. 3A). This revealed that a large frac-
tion of the proteins identified in the IP from HEK293FLAGVCP
lysate had a H/L ratio 1 and thus were enriched relative to
the IP from lysate of control cells. Reducing the IP duration
from 60 min to 30 or even 5 min in the PAM-SILAC protocol
modestly reduced the recovery of FLAGVCP and adaptors
(supplemental Fig. S3B, S3C), but did not significantly atten-
uate exchange (Fig. 3B, supplemental Table S3).
To investigate this further, we repeated the experiment but
with shorter IP intervals ranging from 10 min down to the time
it took to invert a tube five times to mix its contents (“tube
flipping”), prior to collecting the immune complexes in a 1 min
incubation with protein A/G resin. Following the IP step, mass
spectrometry was performed and the SILAC ratios of a subset
of the known VCP adaptors were evaluated. For this analysis,
we focused our attention on UFD1L-NPLOC4 and the UBX
domain adaptors that bind the N-terminal domain and are
thought to promote substrate recruitment. The extremely
short IPs reduced the efficiency of FLAGVCP recovery (al-
though less than might be generally assumed; supplemental
Fig. S3B, S3C). Despite the use of extremely short IP intervals,
we were able to unambiguously measure SILAC ratios for
FLAGVCP and six of its putative substrate adaptors across all
time points. Whereas the SILAC ratios of FLAGVCP peptides
were high, suggesting that protomers within VCP hexamers
FIG. 3. VCP-adaptor complexes
undergo rapid exchange during IP
from cell lysate. A, Schematic work-
flow of IP-MS experiment for study-
ing VCP adaptor exchange. B, Glob-
al protein exchange during IP.
HEK293FLAGVCP and HEK293 cells
were grown in medium containing
“heavy” or “light” lysine plus arginine,
respectively. The cell lysates were
mixed and incubated with anti-FLAG
antibody for the indicated amount of
time prior to collecting immune com-
plexes on protein A/G resin for 5 min.
For “No mixing”, samples were mixed
after the IP step. n  1 for all treat-
ments. C, A repeat of the experiment in
B, except that shorter IP times were
evaluated and the antibody capture in-
terval was reduced to 1 min. “Tube flip-
ping” corresponds to five inversions of
the capped tube. H/L ratios are reported
for VCP and the indicated adaptor pro-
teins. n  1 for all treatments.
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did not exchange rapidly, the peptides recovered from VCP
adaptors had ratios close to 1 suggesting very rapid equili-
bration of the heavy and light adaptors with heavy FLAGVCP
(Fig. 3C, supplemental Table S4). A notable exception is ASP-
SCR1, which was one of the two adaptors that showed strong
cofractionation with VCP by SEC (supplemental Fig. S2A).
Thus, we conclude that the association of FLAGVCP with most
N domain-binding adaptors (and potentially the substrates
that bind to those adaptors) is extraordinarily dynamic, and
thus what one observes by SEC or in a conventional IP is
probably not an accurate reflection of the complexes that
exist in the cell.
Although the IP and SEC experiments both pointed to the
same conclusion, we had some concern that the epitope tag
used for the IP experiments might destabilize the association
of FLAGVCP with its adaptors. To address this issue, we first
compared the proteins recovered after the FLAGVCP IP to
those recovered after IP of endogenous untagged VCP with
an anti-VCP antibody that binds to a C-terminal epitope on
VCP (note that most of the putative substrate-recruitment
adaptors bind to the N-terminal domain of VCP, which is far
from the location of the antibody epitope in the crystal struc-
ture). In this and other experiments (data not shown), we
consistently identified more proteins (supplemental Fig. S3D,
supplemental Table S5), including known VCP adaptors (sup-
plemental Fig. S3E), when we used the anti-VCP antibody,
suggesting that the N-terminal FLAG tag might indeed reduce
the binding of some adaptors. Thus, for future experiments,
we employed the anti-VCP antibody.
VCP-adaptor Interaction is Largely Because Of Direct Bind-
ing—To evaluate whether untagged VCP also exhibits dy-
namic association with its adaptors, we needed to develop a
method to block association of adaptors with endogenous
VCP during the IP step, because it was not possible to per-
form a conventional PAM-SILAC experiment. Because the
epitope recognized by the anti-VCP antibody is in the C-ter-
minal region, we expressed and purified a truncated form of
VCP that incorporates the N and D1 domains as well as a
linker between the D1 and D2 domains (ND1L). ND1L should
bind UFD1L-NPLOC4 and VCP adaptors with a UBX domain
(50) but as expected, it did not bind the anti-VCP antibody
(Fig. 4A). Thus, ND1L added to cell lysates should behave as
a passive sponge that soaks up any adaptors that are either
not bound to VCP or dissociate from VCP during the IP step,
thereby preventing them from rebinding to VCP in the cell
lysate. However, ND1L should have no effect on the koff of
adaptors that are bound to VCP at the time of cell lysis. It
should also not be recovered in the IP step, thereby allowing
us to capture a record of the VCP complexes that pre-existed
in cells and survived the IP step (Fig. 4B). Titration of “light”
ND1L into heavy cell lysate prior to IP with anti-VCP for 1 min
followed by recovery of immune complexes on protein A/G
resin for 5 min reduced the number of proteins recovered (Fig.
4C, supplemental Fig. S4), but had no effect on the recovery
of heavy VCP (Fig. 4D, supplemental Table S6; for this exper-
iment, only C-terminal peptides were counted to rigorously
exclude the possibility that they arose from ND1L). Notably,
addition of ND1L caused a strong reduction in the recovery of
VCP adaptors, with the curious exception of ASPSCR1, and
to a lesser extent UBXN2A (Fig. 4D). ASPSCR1 was also
resistant to exchange in the PAM-SILAC protocol (Fig. 3C)
and both ASPSCR1 and UBXN2A showed good cofraction-
ation with VCP in the SEC analysis (supplemental Fig. S2A).
This experiment suggests two important conclusions: (1)
ND1L does not dislodge stably bound adaptors from VCP,
and (2) most adaptors that bind the N-terminal domain exhibit
extremely dynamic association with untagged endogenous
VCP and dissociate during a 6 min IP.
In-cell Cross-linking Significantly Increases the Recovery of
VCP Adaptors—Given that many VCP-adaptor complexes
were extremely prone to dissociation and exchange in cell
lysate we reasoned that it is not possible to capture a reliable
snapshot of the VCP complexes that existed in a cell using
conventional chromatography or IP methods. Therefore, we
employed a cross-linking agent to “freeze” VCP complexes,
to enable identification of protein interactions that occur in
cells. To trap physiological VCP complexes, we added the
cross-linking agent DSP to intact cells to stabilize complexes
prior to cell lysis. Optimal cross-linking conditions were de-
termined by assessing the formation of high molecular weight
(MW) VCP cross-linked complexes as a function of DSP con-
centration. The lowest concentration of DSP that yielded
near-quantitative cross-linking of VCP was 0.8 mM (Fig. 5A),
and this was therefore employed for subsequent experiments.
When IP with anti-VCP was performed for 2 h, most of the
cross-linked VCP was recovered in the bound fraction (sup-
plemental Fig. S5). SILAC mass spectrometry analysis re-
vealed that cross-linking with 0.8 mM DSP yielded much
higher relative levels of multiple VCP adaptors (with the ex-
ception of the slowly exchanging UBXN2A and ASPSCR1,
which already bound relatively stably in the absence of cross-
linker) than 0.1 mM DSP (Fig. 5B). Notably, the adaptor
UBXN2B/p37, as well as validated VCP interactors NGLY1,
PLAA, and UBE4B were only identified when cells treated with
DSP were used for IP with anti-VCP.
Given the superior ability of the cross-linking method to
identify VCP adaptors, we performed a global SILAC mass
spectrometry analysis in HEK293 cells to identify proteins
whose association with VCP was modulated by either the
allosteric VCP ATPase inhibitor NMS873 (32) or the protea-
some inhibitor MG132. The rationale behind these experi-
ments is that NMS873 might trap VCP in a state that favors
binding of certain adaptor proteins and substrates. By con-
trast, MG132 should prevent the degradation of VCP sub-
strates destined for the proteasome, allowing them to accu-
mulate on VCP. Each SILAC comparison was done in
duplicate, and then the mass labels were swapped and the
experiment repeated in duplicate again. Comparison of bio-
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logical replicates in each case confirmed the robustness of
our methodology (supplemental Figs. S6A, S6B; for a full list
of IDs, see supplemental Table S7). A similar analysis was
done on BJ fibroblasts, although label-free mass spectrome-
try was used instead of SILAC (see supplemental Figs. S6C,
S6D for comparison of replicates and supplemental Table S8
for a full list of IDs). For both experiments, the majority of
proteins with twofold alteration in association with VCP
showed increased (as opposed to reduced) binding in the
presence of NMS873 or MG132, and many of the proteins
that showed enhanced binding in the presence of NMS873
were similarly enriched by MG132 treatment, suggesting that
VCP-interacting proteins are often regulated by the protea-
some (Fig. 6A, 6B). In general, these VCP-interacting proteins
FIG. 4. VCP adaptors undergo dynamic exchange during IP of untagged endogenous VCP. A, VCP antibody does not bind ND1L.
Full-length VCP and the ND1L fragment were fractionated by SDS-PAGE and subjected to Western blotting with anti-VCP. Left panel: Ponceau
S staining of the nitrocellulose filter. Right panel: Western blot of the same filter. B, Schematic workflow of “Sponge” experiment. C, Effect of
ND1L competitor on recovery of VCP-interacting proteins. The indicated amounts of purified ND1L were added to 1 milligram of HEK293 cell
lysate, which was then subjected to IP for 1 min with anti-VCP followed by 5 min with protein A/G resin prior to mass spectrometry. n  1 for
all treatments. D, The relative amounts of individual VCP adaptors identified in the experiment in panel B are plotted. Relative protein amounts
were estimated by LFQ value from MaxQuant.
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appear to be functionally linked to protein biogenesis and
protein quality control, as they are highly enriched for factors
involved in nonsense-mediated decay, translation, amino acid
metabolism, and cotranslational signal recognition particle
(SRP) targeting to membranes (Fig. 6C).
Examination of the VCP adaptors revealed that NMS873
had a profound effect on their assembly with VCP: of the 11 N
domain-binding substrate adaptors identified in both repli-
cates of the HEK293 experiment, two decreased in amount by
at least twofold and five increased in amount by at least
twofold upon inhibition of VCP (Fig. 6D). Qualitatively similar
behavior was observed in the experiment with BJ fibroblasts
(Fig. 6D). The recovery of increased UBXN7 and FAF2 in
association with VCP upon NMS873 treatment is all the more
remarkable given that NMS873 treatment reduces the steady-
state level of these proteins (23). Inhibition of VCP by NMS873
could stabilize association of some adaptors by at least two
conceivable mechanisms. In the first case, NMS873 might
stabilize a conformation of VCP that binds more tightly to
certain adaptors. In the second case, NMS873 might block
degradation of the adaptor or VCP substrates targeted to the
UPS, which upon accumulation bind to their cognate adap-
tors and stabilize their association with VCP. We reasoned
that the second hypothesis could be tested by repeating the
experiment in the presence of the proteasome inhibitor
MG132, which should also block degradation of adaptors and
VCP substrates. In this case, we predict that MG132 would
enhance adaptor association with VCP. However, we only
clearly observed this effect for FAF1 (Fig. 6D), and to a sig-
nificantly lesser extent with UBXN7 (both in HEK293 cells). For
the other three adaptors whose VCP association was en-
hanced by NMS873, MG132 had a relatively negligible effect
in both the HEK293 cells and BJ fibroblasts. This suggests
that NMS873 might act primarily via a direct conformational
effect on VCP.
Bioinformatic Analyses Highlight Similar Responses to VCP
Inhibition in Different Cell Types and Emphasize the Benefit of
Cross-linking—To evaluate the relative performance of the
different approaches taken during the course of this work, we
performed comparative bioinformatic analyses of our data
sets. Fig. 7A charts the behavior of proteins with known VCP
binding motifs (UBX, VBM, PUB, VIM, and PUL domains) as
well as a handful of other well-studied VCP-interacting pro-
teins in AP-MS experiments performed with and without
cross-linking. Some cell type-specific effects are seen (the
most dramatic being the strong association of ERAD compo-
nents AMFR, SYVN1, and DERL2 with VCP in cross-linked BJ
cells treated with NMS873), but for the most part the results
are similar across cell types, with NMS873 consistently en-
hancing VCP association of some adaptors while diminishing
the association of others. Notably, both NMS873 and MG132
enhanced association of ubiquitin with VCP (annotated here
as RPS27A).
Adaptors generally behaved similarly to other adaptors in
their subcategory in response to a variety of conditions, in-
cluding VCP and proteasomal inhibition, as well as during
different types of immunoprecipitation. From this, we specu-
lated we might be able to identify candidate substrates of
these adaptors by querying for proteins with a similar pattern
of variation across the different experiments. Fig. 7B (see
supplemental Fig. S7 for gene names) provides a graphical
representation of the proteins that significantly covaried with
each UBX domain adaptor. Some interesting relationships
worthy of further investigation were noted, including signifi-
cant covariation of UBXN4 with proteasome subunits.
To get a better understanding of how different cell types
and cell treatments (cross-linking or no cross-linking) com-
pared with each other, we constructed Venn diagrams show-
ing the overlap between different experiments. The upper
panel in Fig. 7C shows that 93% of the proteins in HEK293
cells that showed increased binding to VCP upon NMS873
treatment followed by cross-linking, showed the same behav-
ior in similarly treated BJ fibroblasts. By contrast, the overlap
between the data sets from cross-linked and noncross-linked
HEK293 cells was poor (Fig. 7C, lower panel). Given that the
percentage of hits that is independently validated (by cross-
FIG. 5. The crosslinker DSP stabilizes the interaction of VCP
with most of its adaptors. A, DSP was added in the indicated
amounts to HEK293 cells in the absence or presence of DTT for 30
min prior to cell lysis. Cross-linking of VCP was evaluated by frac-
tionation of lysates by SDS-PAGE followed by immunoblotting with
anti-VCP. B, SILAC analysis was performed with heavy—and light—
labeled cells treated with 800 M and 100 M DSP, respectively. The
H/L ratio is reported for the indicated VCP-binding proteins. n  1 for
all treatments.
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referencing with the BioGRID (43) databases) is much higher
for the cross-linked data set, many of the additional hits found
in the noncross-linked sample may be because of higher
nonspecific background. In Fig. 7D, the behavior of the 29
proteins that overlap in the top panel of Fig. 7C is shown
across all experiments performed during the course of this
work. Taken together, these data suggest that cross-linking
yields data sets with the highest enrichment of validated
binding partners (supplemental Table S9). An added benefit of
cross-linking is that it enriches for interactions that occur
within the cell as opposed to in the lysate, where natural
compartment barriers have been breached.
FIG. 6. Chemical inhibition of VCP modulates its repertoire of associated adaptor proteins. A, Effect of NMS873 and MG132 on
VCP-associated proteins in HEK293 cells. Duplicate label-swap SILAC experiments (4 analyses in total) were performed in which cells were either
mock-treated or supplemented with 10 M NMS873 for 6 h, or 10 M MG132 or vehicle (“control”) for 2h. Cells were treated with 800 M DSP for
30 mins prior to cell lysis, mixing of cell lysates, IP with anti-VCP, and SILACmass spectrometry analysis. Number of proteins meeting the indicated
criteria are depicted. B, same as panel A, except that BJ fibroblasts were used, all cells were grown in light medium, and relative protein amounts
were determined by label-free quantification. C, Significant enrichment for gene ontology classes as calculated by PANTHER. All terms with
significance below a certain threshold (p 	 E02 for HEK293 cells; p 	 E09 for BJ cells) are displayed. D, Effect of NMS873 or MG132 treatment
on recovery of the indicated adaptor proteins in the VCP IPs from HEK293 cells (left panel) and BJ fibroblasts (right panel) is plotted. Only adaptors
detected in both replicates for a given cell type are shown. Error bars represent standard error of the mean ratio, n  2.
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FIG. 7. Summary of mass spectrometry results. A, Summary of the impact of MG132 or NMS873 treatment on VCP binding proteins
highlighted by Her et al. (65), in the presence or absence of cross-linking. The final column shows data from (65). The cross-linking data is from
Fig. 6, whereas the noncross-linking experiment (supplemental Table S10) was done separately with HEK293 cells using a similar protocol
except that label-free quantification was used. B, Prediction of potential substrates for UFD1L-NPLOC4 and UBX domain proteins by
covariance analyses. Significance of covariance between UBX domain adaptors and all other proteins identified in the AP-MS experiments
reported here was calculated through Pearson correlation values. All proteins with p 	 0.05 are displayed as a colored circle indicating their
functional categorization. List of proteins for each adaptor can be found in supplemental Fig. S7 and supplemental Table S10. C, Overlap of
AP-MS data for cross-linked HEK293 cells with cross-linked BJ fibroblasts and noncross-linked HEK293 cells. Venn diagram depicts overlap
of proteins with twofold enrichment by NMS873 for each cell type/condition. Numbers in black represent absolute number of proteins,
whereas numbers in red represent percentage of these proteins reported as binding to VCP (as indexed by BioGRID). The dotted arrow signifies
that the 29 proteins that overlap in the upper Venn diagram were used to populate the heatmap in panel D. D, Proteins with2 fold enrichment
by NMS873 in both HEK293 cells and BJ fibroblasts are depicted, as is the behavior of these same proteins in the SEC-mass spectrometry
experiments.
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Dynamic Association of NSFL1C with VCP is an Intrinsic
Property of the Respective Complexes—Both our SEC and IP
mass spectrometry experiments led to the unexpected con-
clusion that adaptor proteins that are known to function with
VCP form extremely dynamic complexes with VCP that un-
dergo rapid dissociation and exchange in cell lysates. We now
sought to both validate these findings and place them on a
more quantitative footing. To this end, we developed a quan-
titative FRET assay that allowed us to measure dynamic as-
sociation of NSFL1C with VCP in vitro. Using the crystal
structure of NSFL1C bound to the N-domain of VCP as a
guide (51), we first mutagenized the C-terminal amino acid
(Thr370) of NSFL1C to cysteine, and then reacted the purified
recombinant protein with maleimide-TAMRA to generate
NSFL1CTAMRA (Fig. 8A). For VCP, we used the ybbR tagging
method (45) to attach a Cy5 tag at its N terminus (Cy5VCP; Fig.
8A). Upon mixing NSFL1CTAMRA and Cy5VCP and exciting
with 540 nm light, we observed a significant reduction in
TAMRA fluorescence coupled to an increase in Cy5 emission
(Fig. 8B). This FRET signal was because of specific interaction
of NSFL1CTAMRA and Cy5VCP, because it was competed by
addition of excess unlabeled VCP (Fig. 8B). By titrating
Cy5VCP, we estimated a Kd of 65 nM for interaction of the two
proteins in the absence of nucleotide (Fig. 8C and Table I).
This affinity is 10-fold tighter than what was reported from
isothermal titration calorimetry studies (52, 53), but is close to
the affinity measured in a pair of surface plasmon resonance
(SPR) studies (20–31 nM) (50, 54). However, there are signif-
icant problems with measuring NSFL1C-VCP interactions by
SPR because of the oligomeric nature of both proteins. In
addition, none of the studies cited above addressed the cru-
cial issue of the dynamics of NSFL1C-VCP interaction. To
investigate binding dynamics, we measured the kon for com-
plex formation and koff for complex dissociation in the ab-
sence of nucleotide (“apo”) or in the presence of ADP or
ATPϒS with and without VCP inhibitors. Examples of koff and
kon measurements in the absence of nucleotide are shown in
Figs. 8D and 8E, respectively, and a plot of kobs versus
[Cy5VCP] that was used to estimate kon is shown in Fig. 8F. As
shown in Table I, kon values were essentially invariant, ranging
from 8–11  107 M1 sec1 regardless of nucleotide state.
Meanwhile, koff showed slightly more variation, ranging from
2.5 s1 in the presence of ATP and NMS873 to 9.5 s1 in the
presence of ADP. Consistent with the lack of an effect of
NMS873 on co-IP of NSFL1C with VCP from lysates of BJ
cells treated with DSP (Fig. 6D), addition of NMS873 in the
presence of ATP had less than a twofold effect on koff (Table
I). These results confirm that purified NSFL1CTAMRA exhibited
extremely dynamic association with purified Cy5VCP in ac-
cordance with the behavior of these proteins in HEK293 cell
extracts, and that their association was relatively insensitive
to modulation by NMS873.
DISCUSSION
We set out in this study with the goal of using size exclusion
chromatography coupled to mass spectrometry to character-
ize VCP-adaptor interactions and identify new VCP-interact-
ing proteins. However, in the course of carrying out these
experiments, we made the surprising finding that VCP shows
little or no cofractionation with adaptors that are well-vali-
dated to bind VCP. Similar results were observed in conven-
tional immunoprecipitation mass spectrometry experiments,
in which SILAC was used to quantify the degree to which
VCP-binding proteins undergo exchange during purification.
Characterization of the interaction between VCP and its adap-
tors has led to two important conclusions. First, under unper-
turbed conditions, VCP dissociates rapidly from all adaptors
in cell lysate except ASPSCR1 and probably UBXN2A. We
were able to reproduce this finding using purified VCP and
NSFL1C, indicating that rapid exchange is likely to be an
intrinsic property of VCP-adaptor interactions. Second, inhi-
bition of VCP ATPase activity with the allosteric inhibitor
NMS873 has markedly distinct effects on the interaction of
different adaptors with VCP. Each of these findings has sig-
nificant implications, which are discussed in more detail in the
following paragraphs.
A Cautionary Note for Analysis of VCP-interacting Pro-
teins—Because the interaction of VCP with its adaptors is so
dynamic, lists of VCP-interacting proteins obtained through
conventional immunoprecipitation protocols (21, 23, 28) are
most likely dominated by proteins that formed interactions
with VCP in cell lysate. Whereas many of these interactions
are nonetheless likely to be physiological, some of them might
not be, because of the loss of compartmentation and other
forms of regulation that accompanies cell lysis. To some
extent adaptor dynamics can be suppressed by NMS873 as
discussed in the next section, but it must be appreciated that
NMS873 has differential effects on adaptors and thus does
not preserve the natural state that existed in cells. The only
strategy we have identified that is likely to adequately sup-
press adaptor exchange is to treat cells with cross-linking
agents prior to cell lysis and IP, but that can carry its own
risks. In the absence of cross-linking, few proteins were iden-
tified that were also found in our cross-linking data–set, and
the majority of these proteins have not been reported to bind
VCP (Fig. 7C, full list can be found in supplemental Table S11).
Therefore, we suspect that VCP-interacting proteins recov-
ered in the absence of cross-linking may not accurately rep-
resent the physiological associations of VCP. We did not
address whether association of proteins with VCP adaptors is
also subject to the same dynamic behavior documented here
for VCP-adaptor interactions, but this possibility should be
borne in mind.
An analysis of the effects of NMS873 on VCP-interacting
proteins appeared while we were finalizing our manuscript
(55). Although their mass spectrometry findings are generally
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consistent with our own (see Fig. 7A for a comparison), their
work focused primarily on mechanisms of VCP resistance to
NMS873 and consequently there are several important differ-
ences with the work reported here. First, their analyses were
performed exclusively under native (i.e. noncross-linked) con-
ditions that favor interactions formed in cell lysate. Second,
our coverage of known VCP interactors was substantially
more comprehensive. Finally, Her et al. did not evaluate the
FIG. 8. Biochemical characterization of VCP-adaptor interactions. A, SDS-PAGE gel of purified recombinant proteins used in this study.
B, Fluorescence emission spectra of 16.7 nM NSFL1CTAMRA trimer, 83.3 nM Cy5VCP hexamer, and a mixture excited at 540 nm shows a 20%
loss of TAMRA donor fluorescence in the presence of Cy5VCP. Loss of fluorescence is prevented by preincubation of NSFL1CTAMRA with 833
nM unlabeled VCP hexamer. C, Equilibrium titration of 50 nM NSFL1CTAMRA trimer with Cy5VCP hexamer. Fit to a quadratic binding equation
yields a KD of 65
 7 nM. Error bars represent
 S.D., with n 3. D, Change in donor fluorescence of 50 nM NSFL1C
TAMRA trimer preincubated
with 300 nM Cy5VCP hexamer upon addition of 3 M unlabeled VCP hexamer in the absence of nucleotide. Curve was fit to a single exponential
to give koff of 4.04 s
1. E, Change in donor fluorescence of 50 nM NSFL1CTAMRA trimer upon addition of Cy5VCP hexamer at various
concentrations in the absence of nucleotide. Curves were fit to a single exponential. F, Exponential fits measured in panel E plotted against
the concentration of Cy5VCP hexamer. Linear slope gives kon of 8.68  10
7 M1s1. Error bars represent 
 S.D., with n  5.
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extent of VCP-adaptor exchange in cell lysate or with purified
proteins.
Dynamics of VCP-adaptor Interactions—The extremely
rapid off-rates that we documented for NSFL1C-VCP com-
plexes pose an interesting question: can VCP-adaptor com-
plexes adequately perform their tasks in cells? VCP has been
reported to have a turnover rate ranging from 0.75–5.2 ATP
per second per hexamer (38, 56–58). Thus, each protomer
turns over less than 1 ATP per second. By comparison, the
slowest koff that we measured for uninhibited VCP-NSFL1C
complexes is 3.3 s1. Comparing these numbers suggests
that, at most, 1 or 2 ATP is hydrolyzed per hexamer during the
lifespan of a VCP-NSFL1C complex, and this is likely to be a
maximal estimate because NSFL1C moderately slows down
ATP hydrolysis by VCP (54, 59). It seems unlikely that this level
of ATP hydrolysis would be sufficient to sustain the proposed
segregase function of VCP. We speculate that there are
mechanisms that modulate the lifespan of VCP-adaptor com-
plexes. Consistent with this idea, NSFL1C forms a tight com-
plex with VCP and copurifies with it from rat liver extracts (60),
whereas we did not observe comigration of these proteins
during SEC of HEK293 cell extracts. Thus, there may exist
factors in liver cells that stabilize VCP-NSFL1C complexes.
This could include covalent modifications on VCP, of which
many have been reported (61), covalent modifications on the
adaptor (62), or engagement of substrate by the adaptor.
In contrast to the behavior of most adaptors, ASPSCR1
(also known as UBXD9, TUG, or ASPL) exhibited relatively
stable binding to VCP in both the IP and SEC protocols. It was
reported previously that the vast majority of ASPSCR1 is
bound to VCP (consistent with our results in the SEC exper-
iment, supplemental Fig. S2A), and disassembles VCP hex-
amers into monomers (63). However, the physiological signif-
icance of this remodeling was not determined. UBXN2A
exhibited a similar behavior to ASPSCR1, but in addition its
expression appeared to depend on the presence of VCP
(supplemental Fig. S2A), suggesting that UBXN2A stability
may be dependent upon its assembly with VCP. Interestingly,
although ASPSCR1 has been linked to GLUT4 trafficking (64)
and UBXN2A to mortalin (65) and nicotinic acetylcholine re-
ceptors (66), neither protein has been shown to link specific
substrates to VCP. Given the distinct VCP binding dynamics
and stoichiometries displayed by UBXN2A and ASPSCR1,
these proteins may not function as substrate adaptors but
instead may sequester or recycle VCP hexamers.
Effects of ATPase Inhibitors on VCP-adaptor Association—
The reversible, competitive VCP ATPase inhibitor CB-5083 is
in clinical development for treatment of cancer. We still know
relatively little about the full range of physiological functions
and regulation of VCP, which creates a challenge for thinking
about the disease settings in which VCP inhibition is likely to
be most efficacious. From this perspective, it is of interest that
the reversible, allosteric VCP ATPase inhibitor NMS873 (32)
exhibited strong differential effects on the association of
adaptors with VCP. An intriguing idea is that, in principal, the
reciprocal should also be true—adaptors whose binding to
VCP is stabilized by an inhibitor should also stabilize binding
of the inhibitor to VCP. This raises the possibility that different
VCP-adaptor complexes might show differential sensitivity to
small molecule inhibition, which has been suggested in prior
studies with NSFL1C (38). Preferential inhibition of particular
VCP-adaptor complexes could be an effective strategy to
focus inhibition on VCP complexes that are of particular im-
portance to the survival of cancer cells that have constitutively
high levels of unfolded protein response (67).
Acknowledgments—We thank the Shu-ou Shan lab for Sfp plas-
mid, T.F. Chou for full-length human VCP in pET15, and S. Bulfer and
M. Arkin for ND1L construct. We thank Shu-ou Shan and members
of the Shan lab for helpful discussion on the FRET assay, Xun Wang
for assistance of VCP tagging by CRISPR technique, and R. Verma
for helpful suggestions and comments on the manuscript. We also
thank Tanya Porras-Yakushi for help in editing the manuscript for
clarity, Annie Moradian and Roxana Eggleston-Rangel for mass
spectrometry support and Michael J. Sweredoski for bioinformatics
assistance.
* This work was supported by the Gordon and Betty Moore Foun-
dation, through Grant GBMF775, the Beckman Institute and the NIH
through Grant 1S10RR029594 (to SH). J.M.R. was supported by a
postdoctoral fellowship from NIH (F32 GM112308-03). R.J.D. is an
Investigator of the Howard Hughes Medical Institute and this work
was funded by HHMI. E.E.B. is supported by an NIH Training Grant
(T32 GM007616). The content is solely the responsibility of the au-
thors and does not necessarily represent the official views of the
National Institutes of Health.
□S This article contains supplemental material.
§§ To whom correspondence should be addressed: Division of
Biology, California Institute of Technology, 1200 E. California Blvd.,
Pasadena, CA. E-mail: deshaies@caltech.edu.
Additional Information: Supplemental data set containing 7 Figs. and
11 Tables. The mass spectrometry proteomics data for supplemental
Table S1, S2, and S5 have been deposited to the Chorus Project
(chorusproject.org) with the project identifier 1068. Other mass spec-
trometry proteomics data have been deposited to ProteomeXchange
TABLE I
Kinetic and equilibrium binding constants for NSFL1CTAMRA and Cy5VCP
Nucleotide state Inhibitor KD (eq) (nM) kon ( 10
7 M1s1) koff (s
1) KD (koff/kon) (nM)
Apo - 65 
 7 8.68 
 0.09 4.04 
 0.09 47
ATPϒS - n.d. 10.5 
 0.1 3.30 
 0.02 31
ADP - n.d. 8.30 
 0.07 9.50 
 0.08 114
Apo CB-5083 n.d. 8.0 
 0.1 4.80 
 0.03 60
ATP NMS-873 n.d. 11.01 
 0.01 2.50 
 0.03 28
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Consortium (http://proteomecentral.proteomexchange.org) via the
PRIDE partner repository (68) with the data set identifier PXD004105.
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